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Introduction. Warfarin is one of the most frequently used anticoagulant agents in the clinic. 
The most important adverse effect of warfarin is hemorrhage of vital organs, such as lung and brain. 
Diffuse Alveolar Hemorrhage (DAH) is a rare clinical condition which occurs due to variety of 
medical disorders. Although it’s rarely reported, DAH can be a result of coagulopathy prompted by 
warfarin therapy. In this study we present a case of DAH, caused by warfarin toxicity which referred 
to the hospital with non-specific respiratory symptoms. 
Case presentation. A 41-year-old female patient referred to the hospital complaining of 
shortness of breath, cough and dizziness. She had been taking warfarin due to mitral valve 
replacement for the past 10 years. Her recent symptoms began shortly after taking amoxicillin, a few 
days before admission. Early clinical examination and paraclinical studies reveal DAH as the cause of 
respiratory symptoms. The patient was then intubated and received fresh frozen plasma, packed cells 
and oral vitamin K. Laboratory findings apart from increased INR, PT, ESR and CRP were all within 
normal range. After the initiation of treatment patient’s INR decreased and her clinical condition 
improved. Follow-up CT-Scan and bronchoscopy also confirmed resolving DAH. 
Conclusions. The usage of warfarin in anticoagulation should be closely monitored due to its 
narrow therapeutic window and other factors, including its interaction with other medications such as 
antibiotics. Warfarin toxicity can lead to DAH, a life-threatening condition which can be presented 
with non-specific symptoms and deteriorate patient’s clinical condition in a short time. Therefore, it is 
of utmost importance to watch closely for primary symptoms of such rare incident in patients under 
warfarin therapy and initiate treatment as soon as possible, to prevent mortality. 
Key words: warfarin, anticoagulant drugs, drug toxicity, hemorrhage, alveoli, pulmonary. 
INTRODUCTION 
Warfarin is one of the most frequently used 
anticoagulant medications in the clinic. However, 
its interaction with other drugs, such as antibiotics, 
alongside its narrow therapeutic window has 
caused different complications due to alteration of 
its efficacy [1]. The most important adverse effect 
of warfarin is hemorrhage of vital organs such as 
lung and brain [2]. Diffuse Alveolar Hemorrhage 
(DAH) is a rare clinical condition which occurs due 
to a variety of medical disorders, such as collagen-
vascular diseases like Wegener’s granulomatosis, 
Goodpasture syndrome, Behḉet’s syndrome, Systemic 
Lupus Erythematosus, Antiphospholipid Antibody 
Syndrome, cardio-pulmonary disorders like pneumonia, 
valvular heart diseases, warfarin drug interactions 
and exposure to toxic agents, other thrombophilic 
conditions and after organ transplantation [3]. The 
incidence of DAH due to warfarin has been reported 
in a small number of studies as a life-threatening 
complication [4].  
In the current report, we present a case of 
DAH in a 41-year-old female which has been 
under warfarin therapy for the past 10 years. She 
referred to the hospital due to cough, respiratory 
distress and dizziness, having had a history of 
amoxicillin consumption for one week before 
admission. 
CASE PRESENTATION 
A 41-year-old female patient referred to the 
hospital for shortness of breath, cough and 
dizziness, starting 3 days before admission. She 
had a history of mitral valve replacement as a 
result of rheumatic mitral stenosis ten years ago, 
and had been under warfarin therapy (7.5 mg 
daily) since then. The latest patient’s documented 
INR level was from 2 weeks before hospital 
admission, which was 2.7. The patient claimed no 
history of labile INR levels and stated that her 
warfarin intake dose hadn’t been changed in the 
last 3 months.  
 The patient claimed that she was non-
smoker. She also stated that 7 days before her 
admission, she started taking amoxicillin due to 
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sinusitis. Antibiotic therapy was continued until 
the day of admission. On the 4th day of taking 
amoxicillin (3 days before hospital admission), she 
began experiencing cough and progressive shortness 
of breath, which she believed was because of her 
sinusitis. Two days later (6 days after beginning of 
her upper sinusitis symptoms and one day before 
hospital admission), she referred to a midwifery 
clinic, complaining from vaginal bleeding and was 
prescribed megestrol (40 mg daily). One day later, 
excessive cough and shortness of breath along with 
severe dizziness determined the patient to refer to 
our hospital. 
Upon admission, vital signs were recorded 
as follows; blood pressure: 90/60 mm Hg, heart rate: 
110 beats per minute, respiratory rate: 32 per minute, 
oxygen saturation without supplemental oxygen: 
70% and 75–80% after initiating 10 lit/min O2 with 
venturi mask. On physical exam, she was pale, 
tachypneic and anxious. In cardiac auscultation, 
tachycardia, irregular S1 and S2 sounds with metallic 
sound and systolic murmur (Intensity: 3/6) on the 
apex was heard. Pulmonary examination revealed 
fine crackles in basal areas of both lungs along 
with reduced vesicular sounds. ECG demonstrated 
Rapid Ventricular Rhythm with Atrial Fibrillation 
(AF). In plain chest radiograph, bilateral perihilar 
and segmental haziness with normal cardio-thoracic 
ratio were visible. Before cardiology consult,  
IV furosemide was initiated for the patient with 
cardiogenic pulmonary edema as primary diagnosis. 
Due to technical laboratory limitations, BNP/NT 
pro-BNP levels were not measured. 
At the emergency department, a Spiral CT-Scan 
was performed, showing segmental air-space filling 
with Hounsfield unit suggesting alveolar hemorrhage, 




Figure 1. First CT-Scan (Parenchymal Window) confirming air-space filling compatible with alveolar hemorrhage. 
 
Notable findings in echocardiography included 
hyperdynamic heart due to tachycardia, normal left 
ventricle and normal right ventricle size and 
function, normal prosthetic mitral valve, Mean 
Pressure Gradient: 4.4 mm Hg, Peak Pressure 
Gradient: 9 mm Hg, moderate tricuspid regurgitation 
and Systolic Pulmonary Artery Pressure: 35 mm 
Hg. Laboratory data were reported as: Hb: 8.5 g/dL 
(normal range: 12–16), WBC: 15000 u/L (normal 
range: 4000–11000), Platelets: 220000 u/L (normal 
range: 150000–450000), PT: 59 sec (normal range: 
0–11), INR: 15, Creatinine: 0.9 mg% (normal range: 
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0.6–1.4), K: 4.3 mEq/L (normal range: 3.5–5.5), 
Na: 136 mEq/L (normal range: 136–145), ESR:  
44 m.m/h (normal range: 0–20), CRP: 192 mg/L 
(normal range: 0–10), RF: negative, ANA: negative, 
Anti-ds DNA: negative, C-ANCA: negative,  
P-ANCA: negative, C3: 97.2 mg/dL (90–180), C4: 
22.5 mg/dL (10–40), d-dimer: 0.2 mg/L (normal 
range: <0.3). 
With DAH as the main diagnosis, due to 
respiratory distress, the patient was sedated and 
subsequently intubated. She received 2 units of fresh 
frozen plasma, 1 unit of packed cells and 5 mg 
vitamin K via NG-Tube.  
Two days later, patient’s INR reduced to 2.6 
and ESR and CRP levels subsided. On the 4th day, 
with good clinical condition, the patient was extubated 
and another CT-Scan was performed which showed 
resolving segments of air-space filling along with 
interlobular septal thickening, compatible with 
natural course of DAH (Figure 2). 
In addition, bronchoscopy was scheduled for 
the following days which also was normal. 
 
 
Figure 2. Follow-up Spiral CT-Scan on the 4th day, compatible with resolving DAH. 
 
DISCUSSION 
As mentioned before, usage of warfarin in 
anticoagulation is limited by an number of factors 
[1]. For instance, antibiotics can interact with warfarin 
in different pathways, including reduction of intestinal 
vitamin K producing bacteria, limitation of vitamin K 
absorption and altering cytochrome p-450 activity, 
thus, predisposing patient to warfarin adverse effects 
such as bleeding [7].  
In a report, Kaya et al. have presented a 
case of DAH in a male patient with history of 
hypertension, diabetes, Mitral Valve Regurgitation 
and chronic renal failure. The authors have stated 
that due to different factors, like diet, alcohol usage, 
consuming other medications during warfarin 
therapy and different patients’ compliances, which 
alter warfarin efficacy, close monitoring of INR is 
needed in patients under warfarin therapy [2].  
In another report, Kiyota et al. discuss a 
similar case of DAH, in an 83-year-old patient, 
who was taking warfarin due to AF, who also had a 
history of rifampicin therapy because of underlying 
bone infection. Their patient presented with 
respiratory distress, hemoptysis and prolonged 
INR, after stopping rifampicin therapy, two months 
before admission. The authors describe the interaction 
of antibiotic consumption with CYP oxidative 
pathways and its possible effect on warfarin 
metabolism [5]. 
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Another case of DAH is reported by Heffler 
et al. in a patient with history of warfarin intake 
due to AF, which had self-increased the dose of 
warfarin from 1.25 mg to 5 mg in the past 8 days 
before admission. The patient had hematuria at the 
time of admission [6].  
Larsen et al. have reported a similar case of 
warfarin toxicity in a patient with dental abscess 
who was treated with amoxicillin/clavulanate and 
was presented with dental bleeding and prolonged 
INR following dental procedure. The authors state 
that even though the prolongation of INR after 
consuming widely prescribed amoxicillin/clavulanate 
in patient under warfarin therapy is rare, it is 
important to be aware of such interaction to avoid 
life-threatening complications [1].  
In our patient, although the daily warfarin dose 
had been relatively high (7.5 mg/day), she had not 
any history of labile INR or subsequent warfarin 
dose modification. However, after consuming 
amoxicillin, she began to show signs and symptoms 
of warfarin toxicity.  
Furthermore, the patient presented in our study 
didn’t have hemoptysis, which is assumed to be 
absent in one-third of DAH cases [8]. As mentioned 
before, DAH is a rare yet a life-threatening 
complication of warfarin therapy and it could be 
represented by non-specific respiratory symptoms. 
In this study, megestrol therapy should be 
considered as a confounding factor. However, lower 
respiratory symptoms in our patient had begun 
before consuming megestrol. Therefore, we believe 
the main interaction in this scenario happened 
between warfarin and amoxicillin. 
We are aware that DAH can happen due to 
variety of reasons [3]. We reached the diagnosis of 
DAH due to warfarin toxicity, since our patient had no 
history indicating other etiologies. For instance, she 
hadn’t had any history of ANCA-associated and non-
ANCA associated pulmonary vasculitides, connective 
tissue diseases, coagulopathies, antiphospholipid 
syndrome, bone marrow transplantation, pulmonary 
veno-occlusive diseases, pulmonary infections or 
malignancies.  
One differential diagnosis for the patient 
could be ARDS due to spreading upper respiratory 
infection, since the patient started taking antibiotics 
due to sinusitis. However, we didn’t find any signs 
or symptoms of upper respiratory infections upon 
her admission. Therefore, the validation of sinusitis 
diagnosis was not possible. Having said that, the 
clinical course, paraclinical and radiological findings 
in the patient was more compatible with DAH rather 
than Acute Respiratory Distress Syndrome or 
pulmonary edema (which was primarily diagnosed 
in the emergency department). 
In conclusion, we believe it is of utmost 
importance to watch closely for primary symptoms 
of toxicity in patients under warfarin therapy along 
with considering DAH as a probable cause of 
respiratory symptoms in such patients and initiate 
required treatments as soon as possible. 
 
 
Introducere. Warfarina este un anticoagulant des utilizat. Unul din efectele 
adverse ale acestuia este sângerarea. Hemoragia difuză alveloară (DAH) este rară 
și apare secundar unor afecțiuni. DAH poate fi declanșată de terapia cu warfarină. 
Prezentăm cazul unei paciente cu DAH determinat de toxicitatea warfarinei. 
Prezentare de caz. O pacientă în vârstă de 41 de ani s-a prezentat la spital 
cu dispnee, tuse și vertij. Pacienta era sunt tratament cu warfarină de 10 ani. 
Simptomele au debutat după ce aceasta a asociat amoxicilină. Evaluarea pacientei 
a relevat DAH. Pacienta a fost intubată și a primit plasmă proaspătă congelată, 
vitamina K și transfuzii. 
Concluzii. Terapia cu warfarină trebuie atent monitorizată și avută în 
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